Although both everolimus and ridaforolimus demonstrated promise in phase I studies, neither of them achieved such promising results in phase II studies in NSCLC patients due to toxicity of these traditional mTOR inhibitors [118,119,120]. This evidence concerns the gene MTOR and non-small cell lung carcinoma.